May 2012 - Page 15 of 20

WednesdayMay 09, 2012 8:58 am

Skinny Nutritional Corp. (SKNY) is “One to Watch”

Skinny Nutritional has established their Skinny Water® brand as a clear alternative to other products in the enhanced water space, with the only true zero calorie, sugar, carb, sodium, and preservative-containing beverage available. Skinny Water’s proprietary formulation of essential antioxidant agents, electrolytes, and the critical vitamins our bodies need in order to achieve optimal function, uses 100% natural flavors, no preservatives, no artificial colors, and only the best purified water. With a wide selection of eight different great tastes to choose from, each designed for a specific function, like Hi-Energy - Acai Grape Blueberry (super charged with B vitamins and…

WednesdayMay 09, 2012 8:57 am

Houston American Energy (HUSA) Closes on Registered Equity Offering

Houston American Energy issued an update to investors on the company’s recent financial and oil and gas operational activity in the United States. Houston American Energy has closed on a direct offering of the company’s common stock to a group of institutional investors. The company sold 6.2 million units at $2.12 per unit, raising gross proceeds of $13.1 million. Houston American Energy reported that each unit consisted of one share of the company’s common stock and one stock purchase warrant. The warrant gives the holder the right to acquire one share of Houston American Energy common stock at an exercise…

WednesdayMay 09, 2012 8:45 am

Rexahn Pharmaceuticals, Inc. (RNN) Submits Phase II Protocol to FDA for Clinical Study of Archexin as Treatment for Ovarian Cancer

Yesterday, clinical stage pharmaceutical company Rexahn Pharmaceuticals, Inc. announced it has submitted a phase II protocol to the U.S. Food and Drug Administration for the clinical study of Archexin(R) as a treatment for ovarian cancer. Archexin is a first-in-class Akt protein kinase inhibitor that has the potential utility to inhibit cancer cell survival and proliferation, angiogenesis, and drug resistance. Based on data from the phase I clinical trial, Archexin has an excellent human safety profile, with fatigue as its only side-effect. Archexin has received FDA Orphan drug designation for five difference cancer types, including renal cell carcinoma, glioblastoma and pancreatic,…

TuesdayMay 08, 2012 5:31 pm

ProGaming Platforms Corp. (PPTF) Global Market Approach

ProGaming Platforms, Israel-based designer of one of the world’s most advanced multi-player online gaming and reward processing platforms, has a clearly developed plan for its entry into the fast-growing global gaming marketplace. Their product is game-independent, a proprietary online gaming and associated billing platform that allows gamers anywhere in the world to compete with one another in games of skill, with as few or as many players as wanted, keeping accurate track of all players and scores, with the winner collecting the winning money or other rewards. A key differentiator is the system’s automatic accounting process, unmatched in the marketplace.…

TuesdayMay 08, 2012 4:08 pm

Infrax Systems, Inc. (IFXY) Introduces SPIDer Detection and Identification Network

Infrax Systems provides unified Smart Grid-related products and services for the energy and utility industries. The company today launched its SPIDer (Secure Perimeter Intrusion Detection) network designed to address the threats of copper theft and malicious attacks on power substations, generation facilities, and critical infrastructure in the electric utility industry. The Department of Energy reports that copper theft, site destruction, and malicious activity generate theft-related costs up to $1 billion nationwide. However, the DoE reports that costs due to the actual theft of the copper are very small compared to the costs to repair the damage to the equipment and…

TuesdayMay 08, 2012 3:23 pm

Zynex, Inc. (ZYXI) Posts Q1 Preliminary Results Lifted by Subsidiary Strength

Zynex, a provider and developer of non-invasive medical devices for electrotherapy and stroke rehabilitation, neurological diagnosis, and cardiac monitoring, today posted its first quarter 2012 unaudited financial results. The company's total first-quarter net revenue increased 35 percent to $8.9 million compared to $6.6 million reported for the first quarter of the year prior. The company attributes the increase in sales to its Zynex Medical subsidiary, in which strong demand continues from its products. A small amount of revenue was derived from its Zynex NeuroDiagnostics subsidiary. First quarter 2012 net income was $320,000, or $0.01 per share, versus a net loss…

TuesdayMay 08, 2012 3:21 pm

Quasar Aerospace Industries, Inc. (QASP) Announces Management Change, CATS Application Approval, and Conference Call Rescheduling

Quasar Aerospace Industries made several announcements today concerning a management change, the acceptance of its CATS (Computer Assisted Testing Service) application, and the rescheduling of a previously announced conference call. Mr. William F. “Bill” Cirmo II has been nominated to fill the void as Chief Operating Officer and would be responsible for overseeing flight training and ground operations for subsidiaries. Mr. Henderson is no longer with the corporation and, in accordance with his employment agreement, has resigned from all positions in Quasar and its subsidiaries. Bill Cirmo began his distinguished career in aviation as an aviator for the US Navy,…

TuesdayMay 08, 2012 2:36 pm

General Market Opportunity for FluoroPharma Medical, Inc. (FPMI)

FluoroPharma Medical is a developer of unique, targeted molecular imaging pharmaceuticals used with positron emission tomography (PET). Although the company is focused primarily on the detection of cardiovascular disease (CAD) related processes, the company has other imaging agents in the pipeline. The company’s market opportunity is based largely upon their lead products: • CardioPET detects regions of metabolic insufficiency, for cardiac viability assessment. • BFPET measures cardiovascular blood flow, and is designed for myocardial perfusion imaging. • VasoPET detects vulnerable coronary artery plaque, an especially dangerous form of plaque. The size of the FluoroPharma market can be viewed as directly…

TuesdayMay 08, 2012 1:24 pm

Phototron Holdings, Inc. (PHOT) Announces Addition to Its Board of Directors

Phototron Holdings is a leading technology supplier to the hydroponic growing industry. The company's line of products include Stealth Grow LED brand LED grow lights and the Phototron single plant systems and accessories. More information on Phototron's products can be found at either www.phototron.com or www.stealthgrow.com. The company today announced that Bob Kurilko, a seasoned executive with over 25 years of experience, has joined its Board of Directors. In this role, Mr. Kurilko will aid in advancing Phototron Holdings' business development goals and assist in guiding its corporate branding and online marketing strategies. He will also be an integral part…

TuesdayMay 08, 2012 1:15 pm

SmallCapVoice: Landis Lifestyle Salons (NXHD) Recognized as Best of State for 2012

Green Endeavors, a majority owned subsidiary of Nexia Holdings, is proud to announce that Landis Lifestyle Salons has been recognized as Best of State-Utah for Hair/Beauty Salons for the second year in a row. The salons will be recognized at the Best of State Awards Gala to be held at the Salt Palace Convention Center on May 22, 2012 in Salt Lake City, Utah. For more information on the award, go to http://bestofstate.org/winner2012_merchandising.html. Landis Lifestyle Salons was also recognized by QSaltLake, a local bi-weekly newspaper in their 2012 Fabby Awards as the best hair salon with the following statement: “Best…

Site Search

Company Search

Month: May 2012